S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden, McCarthy reach final deal to prevent default, now must sell to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden, McCarthy reach final deal to prevent default, now must sell to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden, McCarthy reach final deal to prevent default, now must sell to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
BREAKING: The truth about war with China (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden, McCarthy reach final deal to prevent default, now must sell to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:OCGN

Ocugen (OCGN) Stock Forecast, Price & News

$0.46
+0.01 (+2.21%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.44
$0.47
50-Day Range
$0.45
$0.95
52-Week Range
$0.44
$3.11
Volume
12.25 million shs
Average Volume
8.49 million shs
Market Capitalization
$104.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.90

Ocugen MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
958.3% Upside
$4.90 Price Target
Short Interest
Bearish
18.00% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Ocugen in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.54 out of 5 stars

Medical Sector

921st out of 1,012 stocks

Biological Products, Except Diagnostic Industry

152nd out of 169 stocks


OCGN stock logo

About Ocugen (NASDAQ:OCGN) Stock

Ocugen, Inc. is a biopharmaceutical company founded in 2013, dedicated to developing and commercializing innovative therapies to treat rare eye diseases and other disorders. With a mission to improve patients' lives through cutting-edge research and development, Ocugen is focused on creating transformative treatments that address unmet medical needs.

Headquartered in Malvern, Pennsylvania, Ocugen operates with a global mindset. The company leverages strategic partnerships and collaborations to advance its research and deliver its products worldwide. Ocugen's commitment to innovation and patient-centric solutions has earned it a reputation as a trusted leader in the biotechnology industry.

Ocugen's primary focus is developing gene therapies and biologics for treating rare eye diseases such as inherited retinal disorders and dry eye disease. By harnessing the potential of genetic medicine, Ocugen aims to provide patients with groundbreaking treatments that can significantly improve their quality of life. The company is also actively researching and developing vaccines, including a COVID-19 vaccine candidate.

The target market for Ocugen's products and services includes patients globally suffering from rare eye diseases. By addressing these underserved markets, Ocugen is poised to significantly impact the lives of patients who previously had limited treatment options.

Key customers of Ocugen include healthcare providers, hospitals, clinics, and patients. Ocugen's focus on building solid relationships with key stakeholders has allowed the company to gain traction and establish itself as a trusted partner in the healthcare ecosystem.

In terms of recent achievements, Ocugen has made remarkable progress. The company's most notable milestone was the advancement of its COVID-19 vaccine candidate, COVAXIN, in collaboration with Bharat Biotech. COVAXIN gained emergency use authorization in several countries, including India, and demonstrated promising efficacy against emerging virus variants. This achievement solidified Ocugen's position as a key player in the fight against the COVID-19 virus.

The management team at Ocugen comprises accomplished individuals with diverse backgrounds and extensive industry experience. Dr. Shankar Musunuri, the Chairman, Chief Executive Officer, and Co-Founder, is a seasoned entrepreneur with a successful track record in the biotechnology sector. His leadership has been instrumental in guiding the company's strategic vision and driving its growth. 

Regarding financial performance, Ocugen has not yet achieved profitability, and the stock has continued to drop because the FDA continues to place hold statuses on its developing vaccine and drugs. However, Ocugen's debt levels remain manageable, enabling the company to invest in research and development initiatives without compromising its long-term financial stability. 

Analyzing the company's valuation metrics is crucial in understanding its market positioning. Compared to industry peers, Ocugen's price-to-earnings ratio demonstrates the market's positive sentiment toward the company's growth prospects. Several factors influence the company's valuation. Firstly, the successful advancement of Ocugen's product pipeline, particularly its gene therapies and biologics, contributes to investor optimism. These innovative treatments could revolutionize the field of ophthalmology and address unmet medical needs.

Furthermore, the company's collaboration with Bharat Biotech on the development of COVAXIN has garnered significant attention. The emergency use authorization and promising efficacy data of COVAXIN have positioned Ocugen as a critical player in the global fight against COVID-19 and generated investor confidence in the company's ability to deliver effective vaccines.

However, it's important to note that external factors beyond the company's control can also influence stock prices, such as market conditions, investor sentiment toward the broader biotechnology industry, or geopolitical events. Therefore, thorough analysis and market performance monitoring are essential to understanding Ocugen's stock dynamics.

The biotechnology sector is highly competitive and constantly evolving. Ocugen operates within a niche market of rare eye diseases and genetic therapies, facing both established pharmaceutical companies and emerging biotechnology startups as competitors. Ocugen must maintain a competitive edge by leveraging its innovative technologies, strong research capabilities, and strategic collaborations.

Regulatory and political factors also play a significant role in the biotechnology industry. Changes in regulations or government policies related to drug development, intellectual property rights, or pricing can impact the industry landscape. Ocugen must stay abreast of these developments to ensure compliance and mitigate potential risks.

Looking ahead, Ocugen has several growth opportunities on the horizon. The successful commercialization of its pipeline products has the potential to drive substantial revenue growth. Additionally, the company can explore expansion into new markets and indications, leveraging its expertise in genetic medicine to target other rare diseases beyond ophthalmology.

Furthermore, strategic acquisitions or partnerships with other biotechnology companies can enhance Ocugen's product portfolio and expand its reach. Ocugen can capitalize on its strengths and propel its long-term success by actively pursuing these growth opportunities.

The biotechnology industry has risks and challenges. Market volatility, clinical trial failures, regulatory hurdles, and pricing pressures are among the key risks that Ocugen faces. The company must employ robust risk management strategies to mitigate these challenges effectively.

Ocugen's risk management approach should include diversification of its product pipeline, a thorough evaluation of clinical trial protocols, and proactive engagement with regulatory authorities to navigate the complex regulatory landscape. Furthermore, a comprehensive understanding of the competitive environment and monitoring market trends are crucial to adapt to changing market dynamics.

Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Stock News Headlines

Ocugen (NASDAQ: OCGN)
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
NOTICE: Your retirement is in immediate danger
Soon you may be forced to spend your afternoons packing grocery bags at Walmart instead of going to the park with your grandchildren. Why? Because not only could your money be worth even less than it already is now, but certain stocks and cryptocurrencies could drop by 80%. Even your social security check could be worth 21% less! Learn how to protect your retirement here >>>
H.C. Wainwright Reaffirms Their Buy Rating on Ocugen (OCGN)
Ocugen (NASDAQ:OCGN) PT Raised to $4.00
Ocugen (OCGN) Q1 2023 Earnings Call Transcript
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from HC Wainwright
Analyst Ratings for Ocugen
Mizuho Securities Sticks to Their Buy Rating for Ocugen (OCGN)
See More Headlines
Receive OCGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocugen and its competitors with MarketBeat's FREE daily newsletter.

OCGN Company Calendar

Last Earnings
2/28/2023
Today
5/28/2023
Next Earnings (Estimated)
8/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCGN
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.90
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+958.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-81,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$42.62 million
Book Value
$0.33 per share

Miscellaneous

Free Float
220,067,000
Market Cap
$104.84 million
Optionable
Not Optionable
Beta
3.83

Key Executives

  • Shankar MusunuriShankar Musunuri
    Chairman & Chief Executive Officer
  • Quan Anh Vu
    Chief Financial, Accounting & Business Officer
  • Arun Upadhyay
    Chief Scientific Officer
  • Robert J. Hopkins
    Chief Medical Officer
  • Jesse Simmers
    Head-IT & Facilities













OCGN Stock - Frequently Asked Questions

Should I buy or sell Ocugen stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ocugen in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OCGN shares.
View OCGN analyst ratings
or view top-rated stocks.

What is Ocugen's stock price forecast for 2023?

5 equities research analysts have issued 12 month price objectives for Ocugen's shares. Their OCGN share price forecasts range from $3.00 to $8.00. On average, they predict the company's share price to reach $4.90 in the next year. This suggests a possible upside of 958.3% from the stock's current price.
View analysts price targets for OCGN
or view top-rated stocks among Wall Street analysts.

How have OCGN shares performed in 2023?

Ocugen's stock was trading at $1.30 on January 1st, 2023. Since then, OCGN stock has decreased by 64.4% and is now trading at $0.4630.
View the best growth stocks for 2023 here
.

When is Ocugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 4th 2023.
View our OCGN earnings forecast
.

How were Ocugen's earnings last quarter?

Ocugen, Inc. (NASDAQ:OCGN) posted its quarterly earnings data on Tuesday, February, 28th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01.

What ETFs hold Ocugen's stock?

ETFs with the largest weight of Ocugen (NASDAQ:OCGN) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and ETFMG Treatments Testing and Advancements ETF (GERM).ALPS Medical Breakthroughs ETF (SBIO).

What other stocks do shareholders of Ocugen own?
What is Ocugen's stock symbol?

Ocugen trades on the NASDAQ under the ticker symbol "OCGN."

Who are Ocugen's major shareholders?

Ocugen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.67%), State Street Corp (2.70%), Geode Capital Management LLC (2.06%), JPMorgan Chase & Co. (1.39%), Renaissance Technologies LLC (1.01%) and Charles Schwab Investment Management Inc. (0.67%). Insiders that own company stock include Christopher Dold, Daniel Purefoy, Junge Zhang, Kirsten Castillo, Manish Potti, Prabhavathi Fernandes, Ramesh Kumar, Sanjay Subramanian, Shankar Musunuri, Uday Kompella and Vijay Tammara.
View institutional ownership trends
.

How do I buy shares of Ocugen?

Shares of OCGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocugen's stock price today?

One share of OCGN stock can currently be purchased for approximately $0.46.

How much money does Ocugen make?

Ocugen (NASDAQ:OCGN) has a market capitalization of $104.84 million and generates $42.62 million in revenue each year. The company earns $-81,350,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis.

How can I contact Ocugen?

Ocugen's mailing address is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. The official website for the company is ocugen.com. The company can be reached via phone at (484) 328-4701, via email at ir@ocugen.com, or via fax at 781-547-4452.

This page (NASDAQ:OCGN) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -